Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 19/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4132122 | 0.97 | TLR7 (0.60) | TLR7 | |
| SCHEMBL9936854 | 0.95 | TLR7 (0.62) | TLR7 | |
| SCHEMBL4130549 | 0.93 | TLR7 (0.60) | TLR7 | |
| SCHEMBL30164530 | 0.93 | TLR7 (0.71) | TLR7 | |
| SCHEMBL13798671 | 0.93 | TLR7 (0.71) | TLR7 | |
| SCHEMBL4138771 | 0.91 | TLR7 (0.60) | TLR7 | |
| SCHEMBL5530824 | 0.91 | TLR7 (0.60) | TLR7 | |
| SCHEMBL4126391 | 0.91 | TLR7 (0.60) | TLR7 | |
| SCHEMBL4131529 | 0.91 | TLR7 (0.66) | TLR7 | |
| SCHEMBL4132555 | 0.91 | TLR7 (0.63) | TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090143400-A1 | PURINE DERIVATIVES HAVING IMMUNO-MODULATING PROPERTIES | ASTRAZENECA AB (SE) | 2009-06-04 | — | — | US | claimed |
| EP-3668548-A2 | IMMUNOTHERAPEUTIC TUMOR TREATMENT METHOD | Nektar Therapeutics (US) | 2020-06-24 | — | — | EP | disclosed |
| EP-3628010-A1 | IMMUNOTHERAPEUTIC TUMOR TREATMENT METHOD | Nektar Therapeutics (US) | 2020-04-01 | — | — | EP | disclosed |
| WO-2018204528-A1 | IMMUNOTHERAPEUTIC TUMOR TREATMENT METHOD | NEKTAR THERAPEUTICS (US) | 2018-11-08 | — | — | WO | disclosed |
| US-8865896-B2 | Method for preparing adenine compound | ASTRAZENECA AKTIEBOLAG (SE) | 2014-10-21 | — | — | US | disclosed |
| EP-2246353-A1 | METHOD FOR PRODUCING ADENINE COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2010-11-03 | — | — | EP | disclosed |
| US-20090143400-A1 | PURINE DERIVATIVES HAVING IMMUNO-MODULATING PROPERTIES | ASTRAZENECA AB (SE) | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143400-A1 | PURINE DERIVATIVES HAVING IMMUNO-MODULATING PROPERTIES | IFNG, IFNAR1, IRF3 | TLR7 101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.